Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Mounjaro (tirzepatide) has quickly become one of the most popular GLP-1 medications for weight loss and type 2 diabetes management. But the cost can be a major barrier. In this guide, we break down exactly what Mounjaro costs in 2026 with insurance, without insurance, and through alternative programs that can dramatically lower your out-of-pocket expenses.
Mounjaro Retail Price Without Insurance in 2026
Without insurance or discount programs, Mounjaro carries a list price of approximately $1,000 to $1,200 per month for a 4-week supply. The exact cost varies by pharmacy and dosage level, but this retail price makes it one of the more expensive GLP-1 medications on the market. Most patients find this cost prohibitive, which is why discount programs and insurance coverage strategies are essential.
Mounjaro Cost With Insurance Coverage
With commercial insurance that covers Mounjaro, copays typically range from $25 to $150 per month depending on your plan’s formulary tier and deductible status. However, many insurers have placed Mounjaro on higher tiers or require prior authorization, especially when prescribed for weight loss rather than type 2 diabetes. If your insurance denies coverage, there are several strategies to reduce your costs significantly.
Eli Lilly Savings Card for Mounjaro
Eli Lilly offers a manufacturer savings card that can reduce Mounjaro costs to as low as $25 per month for eligible commercially insured patients. This savings program has specific eligibility requirements and may not apply to patients with government insurance (Medicare, Medicaid, TRICARE). Check the official Lilly website for current program details and restrictions.
Take the Free Eligibility Quiz →
Compounded Tirzepatide as a Lower-Cost Alternative
One of the most popular ways patients access tirzepatide affordably is through compounded tirzepatide programs. These telehealth programs offer compounded versions of the same active ingredient at significantly lower prices, often $300 to $500 per month. While compounded medications are not identical to brand-name Mounjaro, they contain the same active molecule and are prepared by licensed compounding pharmacies.
Mounjaro vs Ozempic: Cost Comparison
When comparing Mounjaro to Ozempic and Wegovy, the costs are relatively similar at retail prices. However, the key differences emerge in insurance coverage patterns and available discount programs. Ozempic tends to have broader insurance coverage due to its longer market presence, while Mounjaro’s dual GIP/GLP-1 mechanism often produces stronger weight loss results in clinical trials. The Mounjaro vs Wegovy comparison is particularly relevant for patients choosing between these options.
How to Get Mounjaro for Less in 2026
Several strategies can help reduce your Mounjaro costs. Check eligibility for the Lilly savings card. Use pharmacy discount tools. Explore compounded tirzepatide through telehealth providers like those in our online GLP-1 programs guide. Appeal insurance denials with your doctor’s help. Compare prices across pharmacies. Many patients find that persistence with insurance appeals and exploring alternative access programs eventually leads to affordable pricing.
Does Medicare Cover Mounjaro?
Medicare Part D may cover Mounjaro when prescribed specifically for type 2 diabetes, but coverage for weight loss alone remains limited. The Inflation Reduction Act has improved some aspects of prescription drug pricing for Medicare beneficiaries, but GLP-1 coverage policies vary significantly by plan. If you have Medicare, contact your plan directly to understand your specific coverage and out-of-pocket costs for tirzepatide.
Take the Free Eligibility Quiz →
Sources & References
- U.S. Food and Drug Administration (FDA) – Drug Approvals and Databases
- National Institutes of Health (NIH) – PubMed Medical Literature
- American Diabetes Association – Medication & Therapies
- Novo Nordisk – Clinical Research Data
- Eli Lilly – Medical Information
This content is regularly reviewed and updated to reflect the latest medical research and FDA guidance.